Articles From: BankFinancial Corporation to Host Conference Call and Webcast on May 2, 2014 to Supertel Hospitality Announces Additional Information on Rights Offering


BURR RIDGE, Ill., April 29, 2014 (GLOBE NEWSWIRE) -- BankFinancial Corporation (Nasdaq:BFIN) will review first quarter 2014 results in a conference call and webcast for stockholders and analysts on Friday, May 2, 2014 at 9:30 a.m. Chicago, Illinois Time.
Sign-up for BankFinancial Corporation to Host Conference Call and Webcast on May 2, 2014 investment picks
RALEIGH, N.C., April 29, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of First Citizens BancShares Inc. (Nasdaq:FCNCA) today declared a quarterly dividend of 30 cents per share on the Class A and Class B common stock.
Sign-up for First Citizens BancShares Declares Dividend investment picks
- Top-line Efficacy Data Expected in 3Q14 - NDA filing expected in 2H15 SALT LAKE CITY, April 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN) , a specialty pharmaceutical company, today announced that the Company has completed enrollment of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study ( http://clinicaltrials.gov/show/NCT02081300 ). The trial is designed to evaluate the safety and efficacy of LPCN 1021, oral testosterone undecanoate ("TU"), in hypogonadal men with low testosterone ("Low T"). The Company expects top-line efficacy data for the trial to be available in the third quarter of 2014, with a New Drug Application ("NDA") filing with the U.S. Food and Drug Administration ("FDA") anticipated in the second half of 2015.
Sign-up for Lipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy investment picks
2014/4/25
PARIS, April 25, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced on World Malaria Day that 300 million treatments of anti-malarial ASAQ Winthrop ® have been delivered in Africa since the medication became available in 2007.
Sign-up for SANOFI : Sanofi Reaches New Milestone in Fight Against Malaria: 300 million ASAQ Treatments Delivered in Africa investment picks
Vitaros ® National Phase Approval Process in Europe Completed SAN DIEGO, April 24, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI) , a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Spanish Agency for Medicines and Health Products (AEMPS) has granted national phase approval to Vitaros ® , Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"). With the approval in Spain, the Company has now received a total of ten national phase approvals for Vitaros ® , including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom (the "U.K.") following its broad approval by European health authorities in June 2013.
Sign-up for Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Spain investment picks
First Quarter Highlights: Operating Earnings of $0.17 per diluted share, excluding restructuring charges GAAP Earnings of $0.15 per diluted share Revenues flat YOY excluding Historic Tax Credit (HTC) asset amortization Net interest income increased 2% YOY driven by balance sheet growth Fees, excluding HTC amortization, decreased 6% YOY driven by lower mortgage banking and capital markets revenues Organic loan growth continues, with average loans up 8% annualized QOQ Average commercial business and real estate loans increased 9% QOQ Momentum in average indirect auto loans continues with $160 million increase Strong credit quality maintained NCOs decreased to 0.36% of average originated loans in the first quarter of 2014 Nonperforming originated loans to originated loans decreased 11 basis points QOQ Successful launch of remote deposit capture mobile
Sign-up for First Niagara Reports First Quarter 2014 Results investment picks
NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas.
Sign-up for Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Advanced Gynecologic Malignancies (SIGN Study) investment picks
2011/04/12
See what we recommend for risk-averse ETF investors.
Sign-up for A Conservative ETF Portfolio for Retirees investment picks
2011/02/14
Morningstar's specialized calculator can work for you.
Sign-up for Find the Right IRA in Three Easy Steps investment picks
2010/09/13
Beware of locking in a low fixed payout.
Sign-up for The Error-Proof Portfolio: For Annuities, Timing Is Key investment picks
2014/5/24
By Jay Ramey An expanded lineup of Beetle-themed cars are in Volkswagen's future, including a Microbus model that we have seen in various concept forms over the past decade, according to Auto Express.
Sign-up for UPDATE: Volkswagen plans return of Microbus investment picks
NEW YORK , May 23, 2014 /PRNewswire/ -- AllianceBernstein Income Fund, Inc. (NYSE: ACG) (the "Fund") today released its monthly portfolio update as of April 30, 2014 .
Sign-up for AllianceBernstein Income Fund Releases Monthly Portfolio Update investment picks
2014/5/23
By Laura He, MarketWatch HONG KONG (MarketWatch) -- Asian stocks were mostly higher on Friday, following a positive U.S. lead, while Thai markets fell after the country's military took control in a coup.
Sign-up for Asian stocks mostly up; Thai markets fall after coup investment picks
http://media.marketwire.com/attachments/201305/156443_calamp.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1112665&ProfileId=051205&sourceType=1 OXNARD, CA --
Sign-up for CalAmp Announces Date for Annual Stockholders Meeting investment picks
TEANECK, N.J. , May 23, 2014 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) , a leading provider of information technology, consulting, and business process outsourcing services, today announced that senior management will present at the following investor conferences: Cowen 42 nd Annual Technology, Media and Telecom Conference Date: Wednesday, May 28, 2014 Time: 10:15 AM ET Presenter: Karen McLoughlin , Chief Financial Officer Sanford C.
Sign-up for Cognizant to Present at Investor Conferences investment picks
DALLAS , May 23, 2014 /PRNewswire/ -- Cross Timbers Royalty Trust (NYSE: CRT) today announced that the Special Meeting of the Trust's unitholders scheduled for today for the purpose of obtaining approval of the appointment of Southwest Bank as successor trustee of the Trust, was adjourned due to the lack of the requisite quorum.
Sign-up for Cross Timbers Royalty Trust Announces Adjournment of Special Meeting investment picks
2014/5/23
MARINA DEL REY, Calif.
Sign-up for Discovery Joint Venture Submits Industrial Hemp License Application investment picks
CHAGRIN FALLS, Ohio , May 23, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces the appointment of Gary Rojewski as its new CEO, effective June 2, 2014 .
Sign-up for EnzymeBioSystems Appoints New Chief Executive Officer investment picks
Company Announcement CHMP recommends marketing authorization for Arzerra in combination with chlorambucil or bendamustine for patients with CLL who have not received prior therapy and are not eligible for fludarabine-based therapy Final decision from European Commission expected in the coming months COPENHAGEN, Denmark, May 23, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation to the terms of the marketing authorization for Arzerra(tm) for a new indication in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Sign-up for GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy investment picks
DALLAS , May 23, 2014 /PRNewswire/ -- U.S. Trust, Bank of America Private Wealth Management, a division of Bank of America, N.A., as Trustee of the Hugoton Royalty Trust (NYSE: HGT) , announced that at the special meeting of the Trust's unitholders held today, the unitholders of the Trust voted to approve the proposal to appoint Southwest Bank as successor trustee to serve as trustee of the Trust once the resignation of the current Trustee of the Trust takes effect.
Sign-up for Hugoton Royalty Trust Announces Unitholder Approval Of Successor Trustee investment picks
2014/5/23
BLUE BELL, Pa.
Sign-up for Inovio Pharmaceuticals Announces 1 For 4 Reverse Split investment picks
NEW YORK , May 23, 2014 /PRNewswire/ -- NorthStar Realty Finance Corp.
Sign-up for NorthStar Realty Finance to Present at NAREIT's REITWeek 2014 Investor Forum on Wednesday, June 4, 2014 investment picks
NEWTON, N.C., May 23, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of Peoples Bancorp of North Carolina, Inc. (Nasdaq:PEBK) declared a cash dividend for the second quarter of 2014 in the amount of $0.04 per share at their most recent meeting.
Sign-up for Peoples Bancorp Announces Cash Dividend investment picks
DALLAS , May 23, 2014 /PRNewswire/ -- Permian Basin Royalty Trust (NYSE: PBT) ("Permian") today announced that the Special Meeting of the Trust's unit holders scheduled for today for the purpose of obtaining approval of the appointment of Southwest Bank as successor trustee of the Trust, was adjourned due to the lack of the requisite quorum.
Sign-up for Permian Basin Royalty Trust Announces Adjournment Of Special Meeting investment picks
WOODBURY, N.Y., May 23, 2014 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq:REFR) announced today its CFO Seth Van Voorhees, will participate in the 11 TH annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28, 2014 in Minneapolis, MN.
Sign-up for Research Frontiers to Participate at Craig-Hallum Institutional Investor Conference on May 28, 2014 investment picks
2014/5/23
Resolute Stockholders Vote in Favor of Each Proposal at Annual Meeting Canada NewsWire Nominees For Withheld Non-Votes   # of shares % # of shares %   Michel P.
Sign-up for Resolute Stockholders Vote in Favor of Each Proposal at Annual Meeting investment picks
NEW YORK (MarketWatch) -- Reynolds American Inc. (RAI) said it is planning to expand manufacturing of its VUSE digital vapor cigarette, adding at least 200 jobs in North Carolina.
Sign-up for Reynolds to expand e-cigarette manufacturing, create 200 jobs investment picks
2014/5/23
NEW YORK , May 23, 2014 /PRNewswire/ -- Pomerantz LLP announces the filing of a class action lawsuit against Allied Nevada Gold Corp.
Sign-up for SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Allied Nevada Gold Corp. and Certain Officers - ANV investment picks
New Board Sets Record Date and Annual Meeting Date CHICAGO , May 23, 2014 /PRNewswire/ -- CommonWealth REIT (NYSE: CWH) announced today that its shareholders elected all seven of the nominees for the Board of Trustees put forth by Related Fund Management LLC and Corvex Management LP at a special meeting of shareholders in Boston .
Sign-up for Shareholders of CommonWealth REIT Elect New Slate of Trustees investment picks
http://media.marketwire.com/attachments/201003/3385_Supertellogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1118355&ProfileId=051205&sourceType=1 NORFOLK, NE --
Sign-up for Supertel Hospitality Announces Additional Information on Rights Offering investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: BankFinancial Corporation to Host Conference Call and Webcast on May 2, 2014 to Supertel Hospitality Announces Additional Information on Rights Offering
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry